Ruijin Neurobank of Alzheimer's Disease and Dementia

Launched by RUIJIN HOSPITAL · Nov 14, 2022

Keywords

ClinConnect Summary

The Ruijin Neurobank of Alzheimer's Disease and Dementia study is looking to understand how changes in the brain and certain biological markers relate to Alzheimer's disease and dementia. Researchers want to know how brain blood flow is affected during the disease process and how different markers associated with Alzheimer's change over time. To do this, they will observe participants, who will visit the research center once a year for a variety of tests, including brain scans (using MRI and PET), memory and thinking assessments, and blood tests.

To be eligible for the study, participants should be between 50 and 90 years old and have been diagnosed with mild cognitive impairment or dementia related to Alzheimer's disease. It's important that participants have a stable caregiver and can understand and complete the necessary tests. The study does not accept individuals with certain other medical conditions or severe psychiatric issues. If you join the study, you can help researchers gain valuable insights into Alzheimer's, which could contribute to better understanding and treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male and female aged 50 to 90 years old;
• • 2. In accordance with the diagnostic criteria for "mild cognitive impairment due to Alzheimer's disease" and "Dementia" from the National Institutes of Health National Institute on Aging-Alzheimer's Association (NIA-AA) (2011);
• • 3. The Hamilton depression rating scale/17 edition (HAMD) total score\<10;
• • 4. The clinical dementia rating (CDR) is 0.5 or above;
• • 5. Neurological examination: no obvious signs;
• • 6. Participants should have a caregiver stable and reliable.
• • 7. Education: primary school (grade 6) or above. They have the ability to complete tests for cognitive ability and have the ability and time to complete regulation of cognitive training
• Exclusion Criteria:
• • 1. Other causes of cognitive decline: cerebrovascular disease, central nervous system infection, CJD, Huntington's and Parkinson's disease, DLB, traumatic brain dementia, other physical and chemical factors (such as drugs, alcohol, CO), systemic disease (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial occupation (a subdural hematoma, brain tumor), the endocrine system disease (thyroid disease, parathyroid disease), and vitamins deficiency or any other causes of dementia.
• • 2. The history of nervous system diseases, including stroke, optic myelitis, Parkinson's disease, epilepsy, etc.);
• • 3. Psychiatric patients, including schizophrenia or other mental illnesses, bipolar disorder, major depression, or delirium;
• • 4. There are unstable or serious heart, lung, liver, kidney, and hematopoietic system diseases; Poor prognosis because of malignant diseases such as tumors.
• • 5. Vision or hearing problems that lead to poor performance on cognitive tests;
• • 6. Two years history of severe alcoholism, and drug abuse;
• • 7. The researchers believe that the subjects could not complete the study.
• • 8. Contraindication of MRI or PET scanning.